NVP-AEW541

NVP-AEW541 is a **small molecule**, potent, and selective inhibitor of **insulin-like growth factor-1 receptor (IGF-1R) kinase**. It is a pyrrolo(2,3-d)pyrimidine derivative. NVP-AEW541 inhibits IGF-I–mediated IGF-1R autophosphorylation, thereby blocking the IGF-IR signaling pathway. It induces cell cycle arrest at the G1/S checkpoint and has antiproliferative and, at higher concentrations, pro-apoptotic effects in several human cancer cell lines, including endometrial carcinoma, breast cancer, biliary tract cancer, and sarcomas. Mechanistically, it suppresses downstream signaling such as AKT and MAPK pathways. It has also demonstrated synergy with chemotherapies like gemcitabine, vincristine, actinomycin D, and ifosfamide in preclinical models. The agent was developed as a targeted therapy for cancer by inhibiting the mitogenic and anti-apoptotic effects mediated by IGF-1R signaling[1][2][3][4].

Other names

AEW541AEW-541AEW 541NVP-AEW541NVP-AEW-541NVP-AEW 541NVP-AEW541-NXNVP-AEW-541-NXNVP-AEW 541-NX